Lancet (London, England)AgedFemaleHumansMaleMiddle Aged
Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.
Jeffrey I Weitz, Aaron P Kithcart, Meagan P O'Brien, Oren Levy, Ethan Marin, Margaret Onisko, Kusha A Mohammadi, Dateng Li, Karoline A Meagher, Hannah H Chang, Benjamin A Olenchock, David E Gutstein, Annelise Segers, Robin S Roberts, Marc P Bonaca
Published: 202510.1016/S0140-6736(25)02097-5
Abstract
BACKGROUND: Coagulation factor XI (FXI) inhibitors can reduce the incidence of thrombosis without increasing bleeding risk. FXI is activated by factor XIIa (FXIIa) or thrombin. REGN7508Cat is an antibody that binds to the FXI catalytic domain, blocki…
Preview only. Read the full abstract at the source